Lessons Learned from CDC's Global COVID-19 Early Warning and Response Surveillance System.

COVID-19 Centers for Disease Control and Prevention Early Warning and Response Surveillance SARS SARS-CoV-2 United States World Health Organization coronavirus coronavirus disease public health surveillance respiratory infections severe acute respiratory syndrome coronavirus 2 validation study viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 15 12 2022
Statut: ppublish

Résumé

Early warning and response surveillance (EWARS) systems were widely used during the early COVID-19 response. Evaluating the effectiveness of EWARS systems is critical to ensuring global health security. We describe the Centers for Disease Control and Prevention (CDC) global COVID-19 EWARS (CDC EWARS) system and the resources CDC used to gather, manage, and analyze publicly available data during the prepandemic period. We evaluated data quality and validity by measuring reporting completeness and compared these with data from Johns Hopkins University, the European Centre for Disease Prevention and Control, and indicator-based data from the World Health Organization. CDC EWARS was integral in guiding CDC's early COVID-19 response but was labor-intensive and became less informative as case-level data decreased and the pandemic evolved. However, CDC EWARS data were similar to those reported by other organizations, confirming the validity of each system and suggesting collaboration could improve EWARS systems during future pandemics.

Identifiants

pubmed: 36502410
doi: 10.3201/eid2813.212544
pmc: PMC9745250
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S8-S16

Références

J Glob Health. 2018 Jun;8(1):010502
pubmed: 29564087
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Emerg Infect Dis. 2020 Nov;26(11):e1-e14
pubmed: 32917290
Ann Glob Health. 2017 May - Aug;83(3-4):625-629
pubmed: 29221538
Lancet Infect Dis. 2020 Nov;20(11):1255-1262
pubmed: 32738203

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH